Not yet recruiting

CAR T Cells in Mesothelin Expressing Cancers

By April 24, 2017 No Comments


Lung Adenocarcinoma|Ovarian Cancer|Peritoneal Carcinoma|Fallopian Tube Cancer|Mesotheliomas Pleural|Mesothelioma Peritoneum

Estimated Enrollment: 30

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: 826085

Study First Received: February 9, 2017

Last Updated: February 10, 2017

Estimated Primary Completion Date: March 2021


Primary Outcome Measures:

Number of participants with treatment-related adverse events as assessed by CTCAE v4.03|Clinical anti-tumor effect by standard criteria (RECIST)|Clinical anti-tumor effect by standard criteria [modified RECIST for mesothelioma]|Progression-free survival|Progression overall survival

Sponsors and Collaborators:

University of Pennsylvania

Website Link:

Leave a Reply

Call Now ButtonCall Now